Specialties: Oncology; Lymphoma

Clinical Interests: Treatment of newly diagnosed PerpheralT cell Lymphoma, including targeted therapy and immunotherapy; relapsed orrefractory Perpheral T cell Lymphoma, especially in ALK positive anaplasticlarge cell lymphoma.

Experience:

1.31^st October to 3^rd November, 2014, in Tokyo, Japan. Annualmeeting of Japan Society of Hematology.

2. 5^th December to 8^th December, 2015, in Orlando, Florida, USA. The 57^th annual meeting of American Society of Hematology.

3. 7^th December to 10^th December, 2019, in Orlando, Florida, USA. The 61^th annual meeting of American Society of Hematology .

Education:

Master of Medicine,Oncology

September,2009--June,2012 Guangdong Provincial Cardiovascular Institute, GaungdongProvince.

Bachelorof Medicine, Clinical Medicine

September,2002--June,2007   Xian’ning Medical college, Hubei Province.

September,1999--June,2002   Songzi No.1 senior middle school,Hubei Province.

September,1996--June,1999   Laocheng junoir middle school, HubeiProvince.

Awards and Honors:

1.Oral: The 15^th Annual meeting of Chinese Society of Clinical Oncology. Chinese Journal ofClinical Oncology,2012,12: BI010.

2. Poster: The 5^th AsiaPacific Lung Cancer Conference and 3^rd International ThymicMalignancy Interest Group Annual Meeting, P1-050.(2012).

3. Poster:The 16^th Annual meeting of Chinese Society of ClinicalOncology.Chinese Journal of Clinical Oncology,2013, 256: HII007.

Professionalmemberships:

Member, LymphomaCommittee of Guangdong Women Doctors Association

Member, Hematoimmunologyof Guangdong Society of Immunology

Member , ChineseSociety of Clinical Oncology

Publications:

1. Ling Huang, She J. An, Zhi H. et al. High-expression of C-MET withwide type EGFR mutation identify a distinct subsets indicative poor prognosisin patients with NSCLC. J Thorac Oncol, 2012, 7(11): s470. (Poster:5th AsiaPacific Lung Cancer Conference and 3rd International Thymic Malignancy InterestGroup Annual Meeting, P1-050).

2. Ling Huang, She-Juan An, Zhi-Hong Chen, Jian Su, Hong-Hong Yan,and Yi-Long Wu. METexpression plays differing roles in Non-Small-Cell LungCancer patients with or without EGFR mutation. J Thorac Oncol, 2014, 9:725–728.

3. Wenyu Li, Ling Huang, HanguoGuo, Xiaojun Wei,Zhanli Liang. Antiviral efficacy analysis of telbivudine concurrent with thefirst cycle of chemotherapy in HBsAg-positive lymphoma patients. J ClinVirol,2014, 61:199-203. (Co-first author)

4. Ling Huang,Fen Zhang, Jialong Zeng, Hanguo Guo, Sichu Liu, Xiaojuan Wei, Feili Chen, XinmiaoJiang, Zhanli Liang, Yanhui Liu, Wenyu Li. ALK expression plays different rolesin anaplastic large-cell lymphomas and outcome of crizotinib use inrelapsed/refractory ALK+ patients in a Chinese population. Ann Hematol, 2018,97:149-159.

5. Chen, C, Liu, S, Jiang, X, Huang, L, et al. Tumor mutation burdenestimated by a

69-gene-panel is associated withoverall survival in patients with diffuse large B-cell

lymphoma. Exp Hematol Oncol. 2021V10N1:20.(Co-first author).

In addition: asCo-author of 6 SCI-indexed papers.